Skip to main content
. 2020 May 28;10(2):153–165. doi: 10.1002/cpdd.817

Figure 4.

Figure 4

Mean (SD) change from baseline in Karolinska Sleepiness Scale (KSS) and number of lapses >500 ms in Psychomotor Vigilance Test (PVT) over the 14‐day average (A: KSS; B: PVT) and on days 2 and 15 (C: KSS; D: PVT) in healthy adult and elderly subjects who received lemborexant for 14 days in Study 002.